Scholarlink

Purpose of Review <p>Long-acting (LA) antiretroviral therapy (ART) is rapidly revolutionizing the landscape of HIV treatment. Clinical trials for injectable cabotegravir/rilpivirine (CAB/RPV) only included certain populations, limiting FDA approval to a subset of people with HIV; frontline medical staff and community members (inclusive of PWH) employed resourcefulness, collaboration, and advocacy to maximize access. However, significant implementation hurdles have constrained uptake, and research about clinical outcomes in PWH who initiate LA-ART with viremia or adherence challenges is nascent.</p> Recent Findings <p>PWH who initiate LAI-ART with viremia, including those with adherence challenges, achieve and maintain viral suppression (VS) at rates similar to PWH who initiate with VS.</p> Summary <p>LAI-ART, in combination with appropriate support and programming, can increase access to ART in PWH with viremia and/or adherence challenges. The overall cost, in terms of dollars and person-time, makes implementation challenging. Additional funding mechanisms are needed, alongside innovative research regarding effective programs and care delivery models, to maximize implementation.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Accelerating Low-Barrier Use of Long-Acting Antiretroviral Therapy to Maximize Impact in People with HIV and Viremia or Adherence Challenges

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2026年7月29日

查看全文
  • Lauren F. Collins,
  • Casey Chmura,
  • Morgan M. Philbin,
  • Jonathan A. Colasanti

摘要

Purpose of Review

Long-acting (LA) antiretroviral therapy (ART) is rapidly revolutionizing the landscape of HIV treatment. Clinical trials for injectable cabotegravir/rilpivirine (CAB/RPV) only included certain populations, limiting FDA approval to a subset of people with HIV; frontline medical staff and community members (inclusive of PWH) employed resourcefulness, collaboration, and advocacy to maximize access. However, significant implementation hurdles have constrained uptake, and research about clinical outcomes in PWH who initiate LA-ART with viremia or adherence challenges is nascent.

Recent Findings

PWH who initiate LAI-ART with viremia, including those with adherence challenges, achieve and maintain viral suppression (VS) at rates similar to PWH who initiate with VS.

Summary

LAI-ART, in combination with appropriate support and programming, can increase access to ART in PWH with viremia and/or adherence challenges. The overall cost, in terms of dollars and person-time, makes implementation challenging. Additional funding mechanisms are needed, alongside innovative research regarding effective programs and care delivery models, to maximize implementation.